#abbvie

[ follow ]
#dividend-investing #pharmaceuticals #dividend-stocks #income-stocks #market-volatility #skyrizi #rinvoq
#dividend-investing
from24/7 Wall St.
2 weeks ago
Business

Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now

Business
from24/7 Wall St.
2 weeks ago

Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now

Realty Income’s valuation and earnings deterioration conflict with dividend-growth claims, while AbbVie offers a lower starting yield with growing dividends supported by earnings.
more#dividend-investing
#dividend-stocks
Business
from24/7 Wall St.
3 weeks ago

10 Years, Zero Regrets: The Dividend Stocks I Keep Buying

Dividend stocks provide passive income and stability, with AbbVie being a strong choice due to its consistent dividend payments and growth potential.
more#dividend-stocks
from24/7 Wall St.
4 weeks ago

Price Prediction: Why AbbVie's Post-Humira Pivot Makes It a Strong Buy

AbbVie reported Q1 2026 revenue of $15 billion, beating the $14.72 billion consensus and growing 12.43% YoY. Adjusted EPS of $2.65 missed by $0.02, but a $744 million IPR&D charge clipped $0.41 per share.
Business
Business
from24/7 Wall St.
1 month ago

Why I Can't Stop Buying AbbVie Stock

AbbVie remains a strong investment due to its reliable dividends, successful product replacements, and undervalued growth potential.
#pfizer
Business
from24/7 Wall St.
1 month ago

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat - The Other Is Praying for a Pipeline Hit

AbbVie reported record net sales driven by Skyrizi and Rinvoq, while Pfizer faced revenue decline due to COVID-related impacts.
Business
from24/7 Wall St.
1 month ago

High Yield vs. Sustainable Growth: Why AbbVie's Dividend Beats Pfizer's Despite the Lower Payout

AbbVie shows strong growth with Skyrizi, while Pfizer struggles with declining COVID revenue and sustainability concerns in dividends.
Business
from24/7 Wall St.
1 month ago

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat - The Other Is Praying for a Pipeline Hit

AbbVie reported record net sales driven by Skyrizi and Rinvoq, while Pfizer faced revenue decline due to COVID-related impacts.
Business
from24/7 Wall St.
1 month ago

High Yield vs. Sustainable Growth: Why AbbVie's Dividend Beats Pfizer's Despite the Lower Payout

AbbVie shows strong growth with Skyrizi, while Pfizer struggles with declining COVID revenue and sustainability concerns in dividends.
more#pfizer
Business
from24/7 Wall St.
1 month ago

AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns

JPMorgan maintains an Overweight rating on AbbVie, viewing recent stock pullback as a buying opportunity with a $260 price target.
Healthcare
from24/7 Wall St.
5 months ago

This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence

Healthcare shows signs of stabilization and potential rebound driven by easing policy risks, clearer earnings, and increased M&A, with AbbVie as a dividend-led candidate.
Medicine
from24/7 Wall St.
7 months ago

Top Dividend Stocks Poised for Explosive Growth in 2026 (ABBV, GD, RGR)

AbbVie shows strong stock performance near analyst targets, offers a 2.79% dividend yield, and markets a novel C‑MET–targeting oncology drug, Emrelis.
[ Load more ]